LTZ-301 / LTZ Therap - LARVOL DELTA

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: LTZ Therapeutics, Inc. | Initiation date: Sep 2025 ➔ Dec 2025

Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: LTZ Therapeutics, Inc.

New P1 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: LTZ Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 (Businesswire) - "LTZ Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL)....LTZ expects to initiate its Phase 1, open-label, multicenter study in Q2 2025."

IND • New P1 trial • Non-Hodgkin’s Lymphoma

LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline (Businesswire) - "LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases...Proceeds from the financing will be used to accelerate development of LTZ’s pipeline, supporting the company’s Investigational New Drug (IND) process, initiating the Phase 1 clinical study of LTZ’s lead asset LTZ-301 as well as the IND-enabling work of its second asset, LTZ-232. The company will also use the new capital to further advance other programs in discovery and to expand its team."

Financing • Hematological Malignancies • Immunology • Lymphoma • Oncology • Solid Tumor